Background: Artificial intelligence-based decision support system (AI-DSS) for frequent insulin dose adjustment was demonstrated to be effective in improving glycemic control in our previous clinical trials. We aimed to assess the effectiveness of AI-DSS in real world diabetes clinics.

Methods: Data was collected and evaluated from routine AI-DSS usage for individuals with type 1 diabetes treated at 21 diabetes clinics (in the USA and 2 in Israel) . Two analyses were made: (1) Insulin dose recommendations were compared for rate of agreement/disagreement between those suggested by the AI-DSS and the approved recommendations by health care providers (HCP) . (2) Glycemic outcomes were compared between baseline and after 3 months of AI-DSS use. Included in this analysis were individuals who had mean baseline glucose level ≥ 182 mg/dL and at least one AI-DSS recommendation within the 3-months.

Results: A total of 8 recommendations, provided to 370 individuals, were evaluated. Full agreement on the direction of insulin dose adjustments was observed in 87%, 87%, and 83% of the basal rate, carbs ratio (CR) , and correction factor (CF) pump settings parameters, respectively. Full disagreement on the direction of dose change was observed in only 0.9%, 0.5%, and 1.2% for the basal rate, CR and CF, respectively. Glycemic outcome analysis included 1 eligible individuals (mean of 1.6 recommendations within a 3-month interval) . Average sensor percentage of time in range [70-180 mg/dL] increased by 4% (p=0.003) : 43% increased time in range by more than 5% and 33% increased by 10% or more. Time in hyperglycemia [> 180 mg/dL] was reduced by 5% (p<0.01) while time in severe hypoglycemia [< 54 mg/dL] remained below 0.5%.

Conclusion: A high rate of agreement with automated insulin adjustments was observed among HCPs at academic centers who used the AI-DSS in their workflow. Glycemic control was significantly improved for sub-optimally controlled individuals already after 3-months of follow up.


R.Nimri: Employee; DreaMed Diabetes, Ltd., Research Support; Abbott Diabetes, Dexcom, Inc., Insulet Corporation, Medtronic, Speaker's Bureau; Eli Lilly and Company, Novo Nordisk, Stock/Shareholder; DreaMed Diabetes, Ltd. A.Tirosh: Advisory Panel; Abbott Diagnostics, AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co., Inc., Novo Nordisk, Sanofi, Consultant; Bayer AG, DreaMed Diabetes, Ltd., Research Support; Medtronic, Speaker's Bureau; Eli Lilly and Company. I.Muller: Board Member; DreaMed Diabetes, Ltd. Y.Shtrit: Employee; DreaMed Diabetes, Ltd. M.Phillip: Advisory Panel; Dompé, Insulet Corporation, Medtronic, Pfizer Inc., Board Member; DreaMed Diabetes, Ltd., Consultant; QuLab Medical Ltd., Other Relationship; Dexcom, Inc., Dompé, DreaMed Diabetes, Ltd., Eli Lilly and Company, Medtronic, NG Solutions Ltd, Novo Nordisk, OPKO, Pfizer Inc., Sanofi, Stock/Shareholder; DreaMed Diabetes, Ltd., NG Solutions Ltd.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at